Multi-omics Market Size, Share, Growth, Trends, and Global Industry Analysis: By Type (Single-cell Multi-omics and Bulk Multi-omics), By Platform (Genomics, Transcriptomics, Proteomics, Metabolomics, and Integrated Omics Platforms), By Indication (Cell Biology, Oncology, Neurology, and Immunology), and By Region (North America, Europe, Asia Pacific, Latin America, and MEA), and Forecast to 2030.

The global multi-omics market was valued at US$ 2,619.5 million in 2024 and is expected to reach US$ 5,974.3 million by 2030, at a CAGR of 12.5% during the forecast period 2024 – 2030. The multi-omics market refers to the sector within biotechnology and bioinformatics that involves the integration and analysis of multiple "omics" data types, such as genomics, proteomics, metabolomics, transcriptomics, and epigenomics. These approaches allow researchers to gain a comprehensive understanding of biological systems by studying various molecular levels simultaneously. The market growth can be attributed to the increasing demand for single-cell multi-omics and advancements in omics technologies. Moreover, the categories, such as genomics, proteomics, metabolomics, and transcriptomics are gaining momentum for healthcare purposes. The COVID-19 pandemic had a positive impact on the industry. The multi-omics approaches have been considered for COVID-19 diagnosis and insights. Various studies and research were conducted to understand the multi-omics role in the COVID-19 diagnosis. For instance, according to the study published by the MDPI in September 2021, multi-omics technology can provide significant new insights to understand COVID-19. Additionally, the emphasis on personalized medicine encourages healthcare providers and researchers to utilize multi-omics technologies to a greater extent. Sharing data is crucial for advancing collaborative multi-omics research but concerns about patient privacy and regulatory compliance can impose limits. This might impede research collaboration and limit access to multi-omics datasets. Regulatory shifts can occur unexpectedly and frequently, necessitating constant monitoring and adaptation by market players. This dynamic environment introduces uncertainty into their operations.

Recent Developments of the Market:

• In January 2024, BD announced the collaboration with Hamilton Company. Through this collaboration, the company focuses on developing robotics-compatible and automated applications reagent kits to standardize and reduce human error in large-scale single-cell multi-omics experiments.
• In January 2024, Thermo Fisher Scientific Inc. collaborated with Akoya Biosciences, Inc. for a license and distribution agreement to deliver a combined solution for spatial multi-omics workflows. The agreement enables a simplified process for whole-slide, multiomic imaging. This combined approach provides a more comprehensive understanding of cell phenotypes and conditions by examining protein and RNA, which is crucial for fields in cancer research.
• In November 2023, Illumina introduced an advanced liquid biopsy assay designed to facilitate comprehensive genomic profiling of solid tumours.